1. Identification of new Priority Substances – state of play
WG E Chemical Aspects
Brussels June 2010
Agenda Item 3(ii)(a)
Helen Clayton
WFD Team
DG Environment
European Commission

2. Sub-Group on Review of Priority Substances meeting of 17-18 May 2010
Discussed the 41 substances on which detailed dossiers had been produced.
Considered principally the following criteria:
PEC/PNEC ratio > 1
PBT/vPvB/carcinogenicity or similar properties
EU relevance, including coverage of monitoring data
Structured the discussion on the basis of a provisional grouping document:
Green = not enough evidence to list at this stage
Red = enough evidence to list
Grey = less obvious, i.e. more discussion/analysis needed
By the end of the discussions: 21 green, 16 red, 4 grey

3. Outcome of the PS SG-R meeting 17-18 May 2010#
Substances
Lead
253
Quinoxyfen
COM 79
Omethoate 47
Dicofol
124
Zinc and its compounds UK 89
Chromium trioxide 10
Edetic acid (EDTA) 7
Cyanides – free (HCN and CN-)
214
Aclonifen 78
Glyphosate FR 77
Amino-methyl phosphonic acid (AMPA)
116
Mecoprop (MCPP)
171
Bentazone IT
204
Propiconazole DE 62
Cyclododecane SE
176
Diphenyl ether, octabromo (octoBDE BDE-197) 26
Bisphenol A (4,4'-isopropylidenediphenol)
384
Clarithromycin
373
Sulfamethoxazole
372
Carbamazepin
377
Diclofenac
378
Ibuprofen
387
17alpha-ethinylestradiol
17 beta-estradiol #
Substances
Lead
101
Chlorothalonil NL 1
Trichlorfon FR 71
Tolylfluanid FI
309
Dichlofluanid
COM
288
Tri-allate UK 28
Musk xylene (5-tert-buthyl-2,4,5-trinitro-m-xylene) AT
334
Methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate (Bifenox)
355
Terbutryn DE
367
Cybutryne (Irgarol®) SE
196
Cypermethrin 13
Dichlorvos
20/ 75
Heptachlor/Heptachlor epoxide 90
Polychlorinated biphenyls (PCBs) 96
Dioxin (2,3,7,8 - Tetrachlorodibenzo-p dioxin,TCDD) IT
?98
Perfluorooctane sulfonic acid and its salts (PFOS) and perfluorooctane sulfonyl fluoride
111/ 172
1,2,5,6,9,10-Hexabromocyclododecane (HBCDD)/ 1,3,5,7,9,11-Hexabromocyclododecane (HBCDD)
224
Alkanes, C14-17, chloro (MCCPs) UK 43
Toluene DK

4. Outstanding issues - the grey substances
Zinc + compounds: ongoing analysis and discussion re monitoring data and PEC/PNEC ratios
Ibuprofen: data awaited on a fish study - October
17 beta-estradiol:
industry paper on PNEC awaited;
further analysis of monitoring data underway;
DK proposal to group EDs.
OctaBDE: resolved, i.e. to consider in context of reviewing existing EQS for BDEs.

5. Outstanding issues - the red substances
Quinoxyfen: ECPA questions PB(T) properties and monitoring data
Diclofenac: EFPIA paper re assessment endpoints
Alpha ethinylestradiol: EFPIA paper re monitoring data
General: right balance of “old” and “current” substances? – consideration of monitoring effort.